Abstract
While germline de novo copy number variants (CNVs) are established causes of autism spectrum disorder (ASD), the contribution of mosaic (early-developmental) copy number variants (mCNVs) has remained largely unexplored. This study assessed the contribution of mCNVs to ASD by analyzing genotype array intensity data from 12,077 ASD probands and 5,500 unaffected siblings across the SSC and SPARK cohorts. The findings reveal that large mCNVs (>4 Mb) are significantly enriched in probands (OR = 11.4), suggesting that these post-fertilization mutations represent a previously unrecognized component of ASD risk.
Introduction
Genetics plays a dominant role in the etiology of autism, yet a significant portion of ASD cases cannot be explained by inherited or de novo germline mutations. Scientists have long hypothesized that "mosaicism"—mutations that arise during embryonic development and exist in only a subset of an individual's cells—might account for some of this missing heritability.
While previous research has linked mosaic single-nucleotide variants (SNVs) to autism, the role of mosaic Copy Number Variants (mCNVs)—large-scale deletions or duplications of DNA—has been difficult to quantify. Because these mutations are not present in every cell, their signal in standard genetic tests is often faint and easily confused with experimental noise. This study utilizes advanced computational methods to distinguish these subtle signals and evaluate their impact on ASD risk.
Methodology
To detect mCNVs, the researchers employed a sophisticated pipeline centered on the MoChA (Mosaic Chromosomal Alterations) caller. This tool analyzes two primary signals from genotype arrays:
- Log-R Ratio (LRR): Measures total DNA intensity to detect gains or losses.
- B-allele Frequency (BAF): Detects imbalances between maternal and paternal DNA contributions.
To maximize sensitivity, the team utilized phased haplotypes. By using parental data to determine which genetic markers sit on the same physical chromosome, they achieved near-perfect long-range phasing. This allowed the detection of mutations present in as few as 3% of the sampled cells. The study analyzed data from the Simons Simplex Collection (SSC) and Simons Powering Autism Research for Knowledge (SPARK), totaling over 17,000 individuals. Findings were compared against a general population sample of 454,993 individuals from the UK Biobank and validated using post-mortem brain tissue from 60 additional probands via whole-genome sequencing and digital droplet PCR (ddPCR).
Key Findings
The Burden of Large mCNVs
The study identified a significant burden of large mCNVs (>4 Mb) in ASD probands. Specifically, 25 probands carried these large events compared to only one unaffected sibling, resulting in an Odds Ratio of 11.4. Interestingly, the researchers did not find mosaic versions of the "classic" recurrent ASD mutations (such as the 16p11.2 deletion). Instead, the mosaic risk stemmed from unique, massive chromosomal rearrangements.
The "Lethality" Hypothesis
A striking observation was the size difference between mosaic and germline mutations. Mosaic CNVs in autism were significantly larger (median 7.8 Mb) than typical germline CNVs (median 0.92 Mb). The authors propose that these massive mutations are only "survivable" because they are mosaic; if such large-scale genomic disruptions were present in every cell (germline), they would likely result in embryonic lethality or miscarriage.
Clinical and Phenotypic Correlation
The study found that the size of the mCNV, rather than the percentage of cells affected (cell fraction), was the primary driver of symptom severity. Increased mCNV size correlated significantly with higher scores on the Social Communication Questionnaire (SCQ) (P = 0.016). In some instances, the mCNVs resulted in "compound heterozygosity." For example, one child possessed a mosaic deletion on one chromosome and an inherited rare variant on the other for the NRXN1 gene, effectively knocking out the gene's function in a subset of cells.
Discussion and Validation
To ensure these findings were relevant to brain development and not merely artifacts of blood or saliva sampling, the team examined post-mortem brain tissue. They successfully validated a complex 10.3 Mb duplication on chromosome 2 in the brain of an individual with ASD, confirming that these early-developmental mutations propagate into the central nervous system.
While these large mosaic events are estimated to explain approximately 0.2% of all ASD cases, they provide a critical window into the biological pathways of the disorder. The results suggest that mosaicism and germline mutations may contribute to ASD through distinct mechanisms, with mosaicism allowing the survival of much larger, more disruptive genomic alterations.
Limitations and Future Directions
Despite the massive dataset, the rarity of mCNVs remains a challenge for identifying recurrent specific mutations. Furthermore, as most data relied on blood or saliva proxies, future research must focus on larger cohorts of brain tissue to fully map how different cell fractions and distributions affect the ASD phenotype. Understanding the environmental or genetic factors that trigger these early-developmental chromosomal instabilities remains a vital next step in autism research.
Summary updated